Altimmune, Inc.
Altimmune, Inc. (ALT): 7 pipeline candidates · ~46 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
46.0 months
D/E 0.18 · 0% dilution
Lead: Phase 2
7 candidates
N/A
10 buys · 0 sells (180d)
A transparent, data-derived signal for Altimmune, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$507.6M
Cash
$97.6M
Quarterly Burn
$20.9M
Runway
46.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| alt wheelchair | — |
| alt wheelchair | — |
| pemvidutide | Phase 2 |
| pemvidutide (ALT-801) | Phase 2 |
| pemvidutide (formerly ALT-801) | Phase 2 |
| standex | — |
| standex | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
171
Total value held
$229.3M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,795,277 | $39.4M |
| vanguard capital management llc | 11,316,098 | $34.9M |
| state street corp | 7,145,550 | $22.0M |
| vanguard portfolio management llc | 5,382,002 | $16.6M |
| marshall wace, llp | 4,017,901 | $12.4M |
| millennium management llc | 3,258,191 | $10.0M |
| geode capital management, llc | 3,107,096 | $9.6M |
| alyeska investment group, l.p. | 2,644,600 | $8.1M |
| two sigma investments, lp | 2,478,900 | $7.6M |
| susquehanna international group, llp | 2,442,356 | $7.5M |
Showing top 10 of 171 institutional holders of Altimmune, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Altimmune, Inc.'s pipeline?
Altimmune, Inc. (ALT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Altimmune, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Altimmune, Inc. has approximately 46.0 months of cash runway.
What is Altimmune, Inc.'s market capitalization?
Altimmune, Inc.'s market capitalization is approximately $507.6M.
Who is the CEO of Altimmune, Inc.?
Mr. Jerome Benedict Durso is the chief executive officer of Altimmune, Inc. (ALT).
Get the full picture on Altimmune, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.